

# Ksenia Matlawska-Wasowska

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7134980/publications.pdf>

Version: 2024-02-01

16  
papers

228  
citations

1162367

8  
h-index

1058022

14  
g-index

16  
all docs

16  
docs citations

16  
times ranked

415  
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug repurposing for targeting cyclic nucleotide transporters in acute leukemias - A missed opportunity. <i>Seminars in Cancer Biology</i> , 2021, 68, 199-208.	4.3	7
2	RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	20
3	<i>TET2</i> and <i>DNMT3A</i> Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors. <i>Cancer Research</i> , 2021, 81, 5089-5101.	0.4	25
4	The Emerging Role of Suppressors of Cytokine Signaling (SOCS) in the Development and Progression of Leukemia. <i>Cancers</i> , 2021, 13, 4000.	1.7	14
5	Metabolic Reprogramming and Cell Adhesion in Acute Leukemia Adaptation to the CNS Niche. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 767510.	1.8	4
6	Epigenetic silencing of <i>SOCS5</i> potentiates <i>JAK-STAT</i> signaling and progression of T cell acute lymphoblastic leukemia. <i>Cancer Science</i> , 2019, 110, 1931-1946.	1.7	24
7	Drugging DNA repair to target T-ALL cells. <i>Leukemia and Lymphoma</i> , 2018, 59, 1746-1749.	0.6	45
8	Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy. <i>PLoS ONE</i> , 2018, 13, e0193849.	1.1	14
9	Dysregulated transcriptional networks in KMT2A- and MLLT10-rearranged T-ALL. <i>Biomarker Research</i> , 2018, 6, 27.	2.8	9
10	High-Throughput Flow Cytometry Identifies Small-Molecule Inhibitors for Drug Repurposing in T-ALL. <i>SLAS Discovery</i> , 2018, 23, 732-741.	1.4	5
11	Eradication of LIG4-deficient glioblastoma cells by the combination of PARP inhibitor and alkylating agent. <i>Oncotarget</i> , 2018, 9, 36867-36877.	0.8	8
12	Integration of ruxolitinib into dose-intensified therapy targeted against a novel <i>JAK2</i> F694L mutation in B precursor acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26328.	0.8	29
13	Cyclic AMP efflux inhibitors as potential therapeutic agents for leukemia. <i>Oncotarget</i> , 2016, 7, 33960-33982.	0.8	20
14	New Insights into Deregulated Gene Expression Pathways in MLL- and AF10-Rearranged T-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 2906-2906.	0.6	0
15	Genome-Based Treatment Algorithm to Prevent Relapse in Children and Young Adults with Acute Lymphoblastic Leukemia: A Prospective Feasibility Study. <i>Blood</i> , 2016, 128, 1738-1738.	0.6	0
16	Pyrosequencing for Classification of Human Fc $\gamma$ RIIIA Allotypes: A Comparison with PCR-Based Techniques. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 665-673.	1.6	4